Literature DB >> 29198891

Observing the advanced disease course in mucopolysaccharidosis, type IIIA; a case series.

Elsa Shapiro1, Alia Ahmed2, Chester Whitley2, Kathleen Delaney3.   

Abstract

This follow-up study of a subgroup of the patients seen in a natural history study of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A) addressed the adaptive and medical characteristics of their advanced disease manifestations. Of the original 24 patients, specific data was collected on only 58% primarily due to difficulty in locating families and coordinating time for interviews two to four years after the original study. At the last contact with the patient, age range was 8 to 24years of age. Data were collected from telephone interviews from the Vineland Adaptive Behavior Scales II and medical and treatment history. We report the case data from rapid progressing and slow progressing patients separately. By the end of our data collection, 5 patients had died; 4 rapid progressing patients between 8 and 12years of age and 1 slow progressing patient at age 21. Two patients were in out-of-home placements in the year before they died. We found that the incidence of surgeries and epilepsy was relatively low and that behavior problems largely subsided. Adaptive levels were very low with children functioning at below a two-year age equivalent level in all adaptive functions, but motor skills were slightly more intact. Only one slow progressing patient was functioning above a three-year level. Parent burden had shifted from behavioral control to physical management. Although their quality of life was clearly negatively impacted by physical management and palliative care, parents were more able to cope and adapt to such demands than in the initial stages of the disease.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adaptive behavior; Advanced stage disease; Mucopolysacharidosis type IIIA; Survival

Mesh:

Year:  2017        PMID: 29198891     DOI: 10.1016/j.ymgme.2017.11.014

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  6 in total

1.  What Can We Learn from the Parents of Children Affected with Mucopolysaccharidosis Type III-A in Israel?

Authors:  Shiri Liber; Orna Staretz-Chacham; Mor Kishon; Ben Pode-Shakked; Odelia Chorin; Katya Kneller; Yair Anikster; Geto Mangisto; Ann Saada; Annick Raas-Rothschild
Journal:  Mol Syndromol       Date:  2021-12-15

2.  Caregivers' assessment of meaningful and relevant clinical outcome assessments for Sanfilippo syndrome.

Authors:  Katherine Ackerman Porter; Cara O'Neill; Elise Drake; Sara M Andrews; Kathleen Delaney; Samantha Parker; Maria L Escolar; Stacey Montgomery; William Moon; Carolyn Worrall; Holly L Peay
Journal:  J Patient Rep Outcomes       Date:  2022-04-25

Review 3.  Sanfilippo Syndrome: Optimizing Care with a Multidisciplinary Approach.

Authors:  Zuzanna Cyske; Paulina Anikiej-Wiczenbach; Karolina Wisniewska; Lidia Gaffke; Karolina Pierzynowska; Arkadiusz Mański; Grzegorz Wegrzyn
Journal:  J Multidiscip Healthc       Date:  2022-09-19

Review 4.  Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease.

Authors:  Rachel Heon-Roberts; Annie L A Nguyen; Alexey V Pshezhetsky
Journal:  J Clin Med       Date:  2020-01-27       Impact factor: 4.241

5.  Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients.

Authors:  Rita Barone; Agata Fiumara; Mariangela Gulisano; Lara Cirnigliaro; Maria Donatella Cocuzza; Claudia Guida; Fabio Pettinato; Filippo Greco; Maurizio Elia; Renata Rizzo
Journal:  Front Neurol       Date:  2021-07-19       Impact factor: 4.003

6.  Early defects in mucopolysaccharidosis type IIIC disrupt excitatory synaptic transmission.

Authors:  Camila Pará; Poulomee Bose; Luigi Bruno; Erika Freemantle; Mahsa Taherzadeh; Xuefang Pan; Chanshuai Han; Peter S McPherson; Jean-Claude Lacaille; Éric Bonneil; Pierre Thibault; Claire O'Leary; Brian Bigger; Carlos Ramon Morales; Graziella Di Cristo; Alexey V Pshezhetsky
Journal:  JCI Insight       Date:  2021-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.